Stay updated with breaking news from Neurology Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis Frexalimab met primary
Investegate announcements from Sanofi, New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021
Tolebrutinib reduced multiple sclerosis (MS) disease activity as measured by MRI - News - PharmaTimes
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 One-year results from Phase 2b extension study of brain-penetrant tolebrutinib